Therapies for Central Serous Chorioretinopathy: A Report by the American Academy of Ophthalmology.
Half-dose photodynamic therapy clears fluid better than no treatment in acute central serous chorioretinopathy
Therapies for Central Serous Chorioretinopathy: A Report by the American Academy of Ophthalmology.
To assess the safety and efficacy of the multiple therapeutic modalities for the treatment of central serous chorioretinopathy (central serous chorioretinopathy).
The panel methodologist assigned a level of evidence rating to each study.
in the treated group, fluid was fully gone at 1 year
Anatomically, the mean CFT at 1 year was significantly lower in the treated group (161 ± 65 μm) versus the observation group (278 ± 92 μm) (P = 0.001).
A second level I study compared half-dose verteporfin photodynamic therapy versus 30%-dose verteporfin photodynamic therapy and found that 94.6% in the half-dose photodynamic therapy group had no subretinal fluid at 12 months compared with 75.4% in the 30%-dose photodynamic therapy group (P = 0.004).
There is evidence to support half-dose photodynamic therapy for the treatment of acute central serous chorioretinopathy regarding anatomic improvement, but less robust evidence supports improvement in visual acuity or sustained anatomic benefit beyond 12 months.
Intravitreal anti-VEGF injections and oral beta-blockers demonstrate inconsistent anatomic and visual benefits in patients with central serous chorioretinopathy.
The mineralocorticoid antagonist eplerenone has not been demonstrated as efficacious for treatment of chronic central serous chorioretinopathy. The treatment of H.